Custom Search

News

Sunday 01 June 2003

Myelopathy from Waldenstrom's macroglobulinemia: improvement after Rituximab therapy.

By: Liberato B, Riethmuller A, Comenzo RL, Lis E, Raizer JJ.

J Neurooncol 2003 Jun;63(2):207-11

Approximately 20% of patients with Waldenstrom's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

Use of this site is subject to the following terms of use